Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hitoshi Takayama

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
Hinyokika Kiyo. Acta Urologica Japonica|May 8, 2010
[Case report of prostatic stromal tumor of uncertain malignant potential (STUMP)]Norihiko Kawamura, Yasutomo Nakai, Noriko Minato, et al.
World Journal of Urology|October 11, 2011
The result of adjuvant chemotherapy for localized pT3 upper urinary tract carcinoma in a multi-institutional studyAtsunari Kawashima, Yasutomo Nakai, Masashi Nakayama, et al.
International Journal of Clinical Oncology|May 11, 2011
Pulmonary metastasectomy in patients with renal cell carcinoma: a single-institution experienceAtsunari Kawashima, Masashi Nakayama, Daizo Oka, et al.
European Journal of Cancer (Oxford, England : 1990)|May 10, 2011
One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patientsAtsunari Kawashima, Hitoshi Takayama, Yasuyuki Arai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2010
Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancerAtsunari Kawashima, Masashi Nakayama, Yoichi Kakuta, et al.
Oncology Letters|July 19, 2012
Co-expression of ERCC1 and Snail is a prognostic but not predictive factor of cisplatin-based neoadjuvant chemotherapy for bladder cancerAtsunari Kawashima, Hitoshi Takayama, Norihiko Kawamura, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|February 3, 2023
[Case of Robot-Assisted Low Anterior Resection with Total Cystectomy for Rectal Cancer Invading the Urinary Bladder/Prostate in Collaboration with Urologists]Yusuke Izutani, Ken Nakata, Hitoshi Takayama, et al.
Scientific Reports|March 31, 2026
Age-stratified trajectories of patient-reported outcomes and perioperative safety after robot-assisted radical prostatectomy: a prospective multicenter cohort studyNorihiko Kawamura, Masashi Nakayama, Yusuke Inagaki, et al.
International Journal of Clinical Oncology|June 13, 2012
Weekly low-dose docetaxel combined with estramustine and dexamethasone for Japanese patients with metastatic castration-resistant prostate cancerKoji Hatano, Kazuo Nishimura, Yasutomo Nakai, et al.
Scientific Reports|October 28, 2021
FAN score comprising fibrosis-4 index, albumin-bilirubin score and neutrophil-lymphocyte ratio is a prognostic marker of urothelial carcinoma patients treated with pembrolizumabAtsunari Kawashima, Yoshiyuki Yamamoto, Mototaka Sato, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Hinyokika Kiyo. Acta Urologica Japonica|May 8, 2010
[Case report of prostatic stromal tumor of uncertain malignant potential (STUMP)]Norihiko Kawamura, Yasutomo Nakai, Noriko Minato, et al.
World Journal of Urology|October 11, 2011
The result of adjuvant chemotherapy for localized pT3 upper urinary tract carcinoma in a multi-institutional studyAtsunari Kawashima, Yasutomo Nakai, Masashi Nakayama, et al.
International Journal of Clinical Oncology|May 11, 2011
Pulmonary metastasectomy in patients with renal cell carcinoma: a single-institution experienceAtsunari Kawashima, Masashi Nakayama, Daizo Oka, et al.
European Journal of Cancer (Oxford, England : 1990)|May 10, 2011
One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patientsAtsunari Kawashima, Hitoshi Takayama, Yasuyuki Arai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2010
Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancerAtsunari Kawashima, Masashi Nakayama, Yoichi Kakuta, et al.
Oncology Letters|July 19, 2012
Co-expression of ERCC1 and Snail is a prognostic but not predictive factor of cisplatin-based neoadjuvant chemotherapy for bladder cancerAtsunari Kawashima, Hitoshi Takayama, Norihiko Kawamura, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|February 3, 2023
[Case of Robot-Assisted Low Anterior Resection with Total Cystectomy for Rectal Cancer Invading the Urinary Bladder/Prostate in Collaboration with Urologists]Yusuke Izutani, Ken Nakata, Hitoshi Takayama, et al.
Scientific Reports|March 31, 2026
Age-stratified trajectories of patient-reported outcomes and perioperative safety after robot-assisted radical prostatectomy: a prospective multicenter cohort studyNorihiko Kawamura, Masashi Nakayama, Yusuke Inagaki, et al.
International Journal of Clinical Oncology|June 13, 2012
Weekly low-dose docetaxel combined with estramustine and dexamethasone for Japanese patients with metastatic castration-resistant prostate cancerKoji Hatano, Kazuo Nishimura, Yasutomo Nakai, et al.
Scientific Reports|October 28, 2021
FAN score comprising fibrosis-4 index, albumin-bilirubin score and neutrophil-lymphocyte ratio is a prognostic marker of urothelial carcinoma patients treated with pembrolizumabAtsunari Kawashima, Yoshiyuki Yamamoto, Mototaka Sato, et al.
Pageof 7